Our latest press releases, media appearances and news commentary.
The February special issue of SLAS Discovery, ‘Advances in Cellular Target Engagement and Target Deconvolution,’ features 11 articles focused on multiple aspects and technologies of cellular target engagement.
Medicines Discovery Catapult, alongside Incisive Health and use MY data published ‘The Issue with Tissue’…
The charity Action on Hearing Loss and Medicines Discovery Catapult announce the launch of the Hearing Medicines Discovery Syndicate.
World-leading drug discovery organisations Charles River Laboratories and Evotec join the Psychiatry Consortium as drug discovery and development partners.
LUNAC Therapeutics (LUNAC) along with the Medicines Discovery Catapult and the University of Leeds, has been awarded £3.14M funding.
Medicines Discovery Catapult recognised at the Bionow Annual Awards 2019, being a finalist for the Bionow Technical Service Award for their Pre-clinical Imaging service.
Strategic collaboration will enable preclinical assessment and inform clinical development strategy for Redx’s Porcupine (RXC006) and ROCK2 inhibitors for fibrotic diseases with high unmet medical need.
Psychiatry Consortium announces its first call for projects that focus on the identification of novel drug targets to address the unmet therapeutic needs of people with mental health conditions.
Cystic Fibrosis Syndicate in Antimicrobial Resistance launches
See how we can help support you with your next drug discovery project.
Speak to us